FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a system for predicting prediction and use of adjuvant chemotherapy for patients with stage II and III gastric cancer, developed algorithm which can predict prediction and responsiveness to chemotherapy using results of quantitative analysis of mRNA expression levels of group associated with prediction or responsiveness to chemotherapy marker genes and group of reference genes in progressive gastric cancer.
EFFECT: invention can be used as additional information for determining a method of treating a gastric cancer patient.
11 cl, 23 dwg, 24 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD OF DETERMINING PROBABILITY OF RECURRENT BREAST CANCER | 2014 |
|
RU2609199C2 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOME OF BREAST CANCER | 2014 |
|
RU2563437C1 |
| METHOD FOR PREDICTING BREAST CANCER RECURRENT DURING ENDOCRINE TREATMENT | 2011 |
|
RU2654587C2 |
